Trial · NCT03652974
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
NCT03652974, Phase 4, Completed, Shanghai Mental Health Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy. Trials, record NCT03652974. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03652974
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
- NCT number
- NCT03652974
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 145 participants, actual
- Lead sponsor
- Shanghai Mental Health Center
- Conditions
- Schizophrenia
- Interventions
- sodium valproate with Clozapine, modified electroconvulsive therapy(MECT) with Clozapine, amisulpride with Clozapine, placebo with Clozapine
- First posted
- 2018-08-31
- Last updated
- 2022-09-06
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Positive and Negative Syndrome Scale (PANSS) | the baseline | The battery of Positive and Negative Syndrome Scale (PANSS) test will be administered in a 30-minute sessions to evaluate the psychiatric symptoms. |
| Primary | Positive and Negative Syndrome Scale (PANSS) | the end of the six week | The battery of Positive and Negative Syndrome Scale (PANSS) test will be administered in a 30-minute sessions to evaluate the psychiatric symptoms. |
| Primary | Positive and Negative Syndrome Scale (PANSS) | the end of the twelve week | The battery of Positive and Negative Syndrome Scale (PANSS) test will be administered in a 30-minute sessions to evaluate the psychiatric symptoms. |
| Primary | Scale for the Assessment of Negative Symptoms (SANS) | the baseline | The Scale for the Assessment of Negative Symptoms (SANS) was applied to assess negative symptoms. |
| Primary | Scale for the Assessment of Negative Symptoms (SANS) | the end of the six week | The Scale for the Assessment of Negative Symptoms (SANS) was applied to assess negative symptoms. |
| Primary | Scale for the Assessment of Negative Symptoms (SANS) | the end of the twelve week | The Scale for the Assessment of Negative Symptoms (SANS) was applied to assess negative symptoms. |
| Primary | Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) | the baseline | The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) was used to evaluate the cognitive performance. |
| Primary | Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) | the end of the six week | The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) was used to evaluate the cognitive performance. |
| Primary | Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) | the end of the twelve week | The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) was used to evaluate the cognitive performance. |
| Primary | Clinical Global Impression (CGI) | the baseline | The Clinical Global Impression (CGI) including severity scale (CGI-S), improvement scale (CGI-I), and efficacy index (CGI-E) was used to evaluate the severity of symptoms and treatment response and treatment effect, respectively. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 36253804 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03652974
GET https://conductscience.org/api/trials/v1/NCT03652974/registered